Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Investor Presentation (August 2025)
8 slides from Nova Eye Medical's investor presentation, Aug 27, 2025
Slide 1: Investor Presentation: Results for the Year ended 30 June 2025
Nova Eye Medical Limited (ASX:EYE) Investor Presentation Results for the Year ended 30 June 2025 nova-eye.com | 1 27 August 2025
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any st
Slide 3: Sales Growth in all Territories
Sales Growth in all Territories Growth US$'000’s FY24 H1FY25 H2FY25 FY25 on PCP USA 11,383 6,477 7,832 14,309 26% Germany 1,631 869 1,040 1,909 17% Rest of World 1,228 329 1,069 1,399 14% Sales (Excl China) 14,242 7,674 9,942 17,616 24% China 996 710 452 1,162 17% Total Sales US$ 15,238 8,384 10,393
Slide 4: Six consecutive halves of sales growth in USA
Six consecutive halves of sales growth in USA USA sales growth FY23 to H2FY25 9,000,000 8,000,000 7,000,000 6,000,000 5,000,000 USA$ 4,000,000 3,000,000 2,000,000 1,000,000 - H1 FY23 H2FY23 H1FY24 H2FY24 H1FY25 H2FY25 • Continued revenue growth with another record half in USA nova-eye.com | 4
Slide 5: Key Operating Results
Key Operating Results • Gross margin improvement from 66% in H1FY25 to 70% in H2FY25 due to process improvements • Operating expenditure as a percentage of sales fell to 70% in H2FY25 down from 88% in H1FY25 and 83% in FY24, demonstrating operating leverage • Cash outflow from operations for FY25 wa
Slide 6: Key Operating Results details (A$ audited)
Key Operating Results details (A$ audited) FY24 ACT H1FY25 H2FY25 FY25 ACT H1FY25(3) H2FY25 FY25 ACT(4) A$000’s A$'000s A$000's A$ 000"s US$'000s US$000's US$ 000"s Revenue Glaucoma 23,147 12,838 16,239 29,077(1) 8,384 10,393 18,777 Growth on pcp 51% 23% 51% 23% COGS (6,487) (4,363) (4,831) (9,194)
Slide 7: FY26 Update and Guidance
FY26 Update and Guidance • Sales for July 2025 were in line with target • FY26 sales revenue (excluding China) expected to range between US$21 million and US$24 million (A$32 million to A$37 million at todays’ exchange rate) • The group is currently expected to achieve breakeven EBITDA in H1 FY26 •
Slide 8: Tom Spurling Mark Flynn
Tom Spurling Mark Flynn Managing Director Investor Relations +61 8 8362 0193 +61 416 068 733 tspurling@nova-eye.com mflynn@nova-eye.com nova-eye.com | 8
Nova Eye Medical — Investor Presentation (August 2025) on 6ix